Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Marie Skłodowska-Curie Action · Running

RAS-PUNCH Delivering a '1-2 punch' to RAS-driven cancers

Coordinator
Karolinska Institutet, Sweden
Runs
1 November 2026 to 31 October 2028
Status
Running
EU funding
€236k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101274380

What the project is doing

In the project's own words, from its summary on CORDIS.

Resistance to current anticancer therapies remains a major public health burden, driving a substantial number of cancer-related deaths in the EU and worldwide. In particular, KRAS-driven lung cancer – one of the most aggressive tumour types – urgently requires new strategies, as resistance to the approved KRAS-G12C inhibitors almost invariably emerges within months after treatment, undermining their clinical benefit. Mounting evidence highlights that cancer cells can adopt a dynamic and heterogeneous tolerant state early upon treatment, allowing the survival of a small fraction of cancer cells that later fuels resistance and, ultimately, patient relapse.

Yet, targeting this tolerant phase remains insufficiently explored to translate to clinical practice that proactively targets cancer resistance. Therefore, RAS-PUNCH aims to overcome this challenge by pioneering a sequential ‘1-2 punch’ strategy that first reprograms and then eliminates tolerant cells in KRAS-driven lung cancer, building on their unique dynamic and heterogeneous nature. Moving beyond conventional strategies, RAS-PUNCH will comprehensively define the phenotypic plasticity underlying RAS inhibitor-induced tolerance, identify small molecule ‘reprogrammers’ through high-throughput phenotypic screening and integrate them into a preclinical ‘1-2 punch’ framework.

By delivering the first phenotypic atlas of RAS inhibitor-induced heterogeneity and advancing mechanistically informed ‘1-2 punch’ strategies, RAS-PUNCH addresses a central unmet need in oncology. The expected outcomes will provide proof-of-concept for innovative sequential treatments that prevent resistance in lung cancer, with potential to extend across multiple cancer types. In doing so, the project directly contributes to the EU Cancer Mission’s ambition of saving and improving the lives of cancer patients.

Topics

Who is involved

OrganisationCityCountryRole
Karolinska InstitutetStockholmSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI